Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer

This phase II trial evaluates the effect of capecitabine on tumor response using imaging and tumor markers to adjust dose (adaptive therapy) in patients with estrogen receptor (ER) positive, HER2 negative breast cancer that has spread from where it first started to other areas in the body (metastatic). Capecitabine is in a class of medications called antimetabolites. It is taken up by tumor cells and breaks down into fluorouracil, a substance that kills tumor cells. Adaptive therapy with capecitabine based on tumor burden response may slow or stop the growth of tumor cells in patients with met

Trial Details

NCT ID
NCT06525766
Phase
PHASE2
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Biospecimen Collection
  • Bone Scan
  • Capecitabine
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Questionnaire Administration
Locations (sample)
  • Scottsdale, Arizona, United States|33.50921,-111.89903

Key Eligibility Criteria

  • PRE-REGISTRATION: Provide written informed consent Note: Pre-registration should occur prior to screening research blood draws being completed
  • PRE-REGISTRATION: Provider anticipates the patient will begin on capecitabine within 14 days or has started capecitabine within the past 42 days an…
  • REGISTRATION - INCLUSION CRITERIA
  • Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →